trending Market Intelligence /marketintelligence/en/news-insights/trending/b1ajewi-hayygihovnuj0q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Synthetic Biologics prices $18M securities offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Synthetic Biologics prices $18M securities offering

Synthetic Biologics Inc. priced an underwritten public offering for a combination of securities to raise $18 million in gross proceeds.

The company is offering class A units consisting of 2,520,000 common shares and warrants to purchase 2,520,000 shares at a combined price of $1.15, and class B units consisting of 15,102 series B convertible preferred shares convertible into an aggregate of 13,132,173 common shares, and warrants to purchase 13,132,173 common shares.

The warrants will be exercisable upon issuance at an exercise price of $1.38 and will expire five years after issuance.

Synthetic Biologics has given underwriters the option to purchase up to an additional 15% of the common shares, warrants and common shares issued after conversion of preferred shares.

The company plans to use net proceeds from the offering to fund preclinical and clinical programs. In addition, it expects to use the proceeds for working capital and general corporate purposes.

The offering is expected to close Oct. 15, subject to customary closing conditions.

Alliance Global Partners is acting as the sole book-running manager for the offering.